Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines

Cancer Research

Volumn 61, Issue 19, 2001, Pages 7217-7224

  Gourdeau, Henriette ^a   Clarke, Marilyn L ^b,c   Ouellet, France ^a   Mowles, Delores ^c   Selner, Milada ^c   Richard, Annie ^a   Lee, Nola ^a   Mackey, John R ^b,c   Young, James D ^b   Jolivet, Jacques ^a   Lafrenière, Ronald G ^a   Cass, Carol E ^b,c  

^a Shire Canada   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; CYTIDINE DERIVATIVE; DEOXYCYTIDINE DERIVATIVE; GEMCITABINE; NUCLEOSIDE DERIVATIVE; TROXACITABINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; DRUG EFFECT; DRUG TRANSPORT; HUMAN; HUMAN CELL; NUCLEOSIDE TRANSPORT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SOLID TUMOR; UTERINE CERVIX CARCINOMA;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; CYTARABINE; CYTIDINE DEAMINASE; CYTOSINE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DIOXOLANES; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA; MALE; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; NUCLEOSIDE TRANSPORT PROTEINS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; SEQUENCE HOMOLOGY, AMINO ACID; SODIUM; STEREOISOMERISM; TRITIUM; TUMOR CELLS, CULTURED; URIDINE;

EID: 0035476267     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Comparative study of a novel nucleoside analogue (Troxatyl™, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity
2. Anticancer activity of a novel nucleoside analogue with the unnatural L configuration
3. Potent antitumor activity of a novel nucleoside analogue: BCH-4556 (β-L-dioxolane-cytidine) in human renal cell carcinoma xenograft tumor models
4. Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastasis in vitro and in vivo
5. The new dioxolane, (-)-2′-deoxy-3′-oxacytidine (BCH-4556, troxacitubine), has activity against pancreatic human xenografts
6. L- and D-enantiomers of 2′, 3′-dideoxycytidine 5′-triphosphate analogs as substrates for human DNA polymerases
7. Preclinical characteristics of gemcitabine
8. Action of 2′2-difluorodeoxycytidine on DNA synthesis
9. Ara-C: Cellular and molecular pharmacology
10. Effects of 1-β-D-arabinofuranosylcytosine incorporation on elongation of specific DNA sequences by DNA polymerase β
11. Uptake and metabolism of the new anticancer compound β-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells
12. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines
13. Gemcitabine transport in Xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters
14. Dideoxycytidine metabolism in wild type and mutant CEM cells deficient in nucleoside transport or deoxycytidine kinase
15. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein
16. Nucleoside transporters of mammalian cells
17. Nucleoside transporters: Molecular biology and implications for therapeutic development
18. Nucleoside transporter proteins: Emerging targets for drug discovery
19. The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase
20. Structure-activity relationship among a new class of antiviral and heterosubstituted 2′, 3′-dideoxynucleoside analogues
21. Differences in metabolism and cytotoxicity between 9-β-D-arabinofuranosyladenine and 9-β-D-arabinofuranosyl-2-fluoradenine in human leukemic lymphoblasts
22. +-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system. cib)
23. +-nucleoside cotransporter (hCNT1)
24. +/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine
25. Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1
26. Functional characterization of a recombinant sodium-dependent nucleoside transporter with selectivity for pyrimidine nucleosides (cNT1rat) by transient expression in cultured mammalian cells
27. Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells
28. Initial rate kinetics of the transport of adenosine and 4-amino-7-(β-D-ribofuranosyl)pyrrolo[2, 3-d]pyrimidine (tubercidin) in cultured cells
29. Schedule dependence of sensitivity to 2′, 2′-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours
30. Induction of resistance to 2′, 2′-difluorodeoxycytidine in the human ovarian cancer cell line A2780
31. Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts
32. Mutational analysis of nucleoside and nucleobase transport
33. Plasma membrane transport of nucleosides, nucleobases and nucleotides: An overview
34. Expression of high levels of nitrobenzylthioinosine-sensitive nucleoside transport in cultured human choriocarcinoma (BeWo) cells
35. Phosphorylation of 2′, 3′-dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells
36. Human cytidine deaminase: Purification of the enzyme, cloning, and expression of its complimentary DNA
37. Effect of tetrahydrouridine on metabolism and transport of 1-β-D-arabinofuranosylcytosine in human cells
38. Decreased resistance to gemcitabine (2′, 2′-difluorodeoxycytidine) of 1-β-D-arabinofuranosylcytosine-resistant myeloblastic murine and rat leukemia cell lines: Role of altered activity and substrate specificity of deoxycytidine kinase
39. Cross-resistance in the 2′, 2′-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs
40. Identification of the mechanism of activation of 9-β-D-arabinofuranosyladenine in human lymphoid cells using mutants deficient in nucleoside kinases
41. Nucleoside transport in normal and neoplastic cells
42. Identification and reconstitution of the nucleoside transporter of CEM human leukemia cells
43. 3H]L-adenosine in DDT] MF-2 smooth muscle cells
44. Enantiomeric selectivity of adenosine transport systems in mouse erythrocytes and L1210 cells
45. Kinetic and allosteric cooperativity in L-adenosine transport in chromaffin cells. A mnemonical transporter
46. Resistance to 1-β-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene
47. Studies of the enzymatic deamination of ara-cytidine. V. Inhibition in vitro and in vivo by tetrahydrouridine and other reduced pyrimidine nucleosides
48. High susceptibility of human cancer xenografts with higher levels of cytidine deaminase to a 2′-deoxycytidine antimetabolite, 2′-deoxy-2′-methylidenecytidine
49. Phase I study of BCH-4556 in patients with advanced leukemia